DE69914360D1 - Chromone zubereitung zur enteralen wirkstofffreisetzung - Google Patents

Chromone zubereitung zur enteralen wirkstofffreisetzung

Info

Publication number
DE69914360D1
DE69914360D1 DE69914360T DE69914360T DE69914360D1 DE 69914360 D1 DE69914360 D1 DE 69914360D1 DE 69914360 T DE69914360 T DE 69914360T DE 69914360 T DE69914360 T DE 69914360T DE 69914360 D1 DE69914360 D1 DE 69914360D1
Authority
DE
Germany
Prior art keywords
chromone
enteral
preparation
active substance
substance release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69914360T
Other languages
English (en)
Other versions
DE69914360T2 (de
Inventor
Alexander James Wigmore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tr Healthcare Ltd Linthwaite Huddersfield Gb
Original Assignee
Hewlett Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hewlett Healthcare Ltd filed Critical Hewlett Healthcare Ltd
Publication of DE69914360D1 publication Critical patent/DE69914360D1/de
Application granted granted Critical
Publication of DE69914360T2 publication Critical patent/DE69914360T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5015—Organic compounds, e.g. fats, sugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Manufacturing Of Magnetic Record Carriers (AREA)
  • Medicines Containing Plant Substances (AREA)
DE69914360T 1998-11-11 1999-11-09 Chromone zubereitung zur enteralen wirkstofffreisetzung Expired - Lifetime DE69914360T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9824604 1998-11-11
GBGB9824604.4A GB9824604D0 (en) 1998-11-11 1998-11-11 Treatment of allergic conditions
PCT/GB1999/003731 WO2000027392A1 (en) 1998-11-11 1999-11-09 Chromone enteric release formulation

Publications (2)

Publication Number Publication Date
DE69914360D1 true DE69914360D1 (de) 2004-02-26
DE69914360T2 DE69914360T2 (de) 2004-11-11

Family

ID=10842171

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69914360T Expired - Lifetime DE69914360T2 (de) 1998-11-11 1999-11-09 Chromone zubereitung zur enteralen wirkstofffreisetzung

Country Status (12)

Country Link
US (2) US7258872B1 (de)
EP (1) EP1128826B1 (de)
JP (1) JP4558207B2 (de)
AT (1) ATE258049T1 (de)
AU (1) AU1061400A (de)
CA (1) CA2350519C (de)
DE (1) DE69914360T2 (de)
DK (1) DK1128826T3 (de)
ES (1) ES2219075T3 (de)
GB (1) GB9824604D0 (de)
PT (1) PT1128826E (de)
WO (1) WO2000027392A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
AU2001296770A1 (en) * 2000-10-06 2002-04-15 Durect Corporation Devices and methods for management of inflammation
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CA2466863A1 (en) * 2001-11-29 2003-06-05 Emisphere Technologies, Inc. Oral pharmaceutical compositions comprising cromolyn sodium and an acylated amino acid
US8263645B2 (en) * 2006-02-03 2012-09-11 Pari Pharma Gmbh Disodium cromoglycate compositions and methods for administering same
US8817116B2 (en) 2011-10-28 2014-08-26 Lg Innotek Co., Ltd. Camera module
PL3104853T3 (pl) 2014-02-10 2020-05-18 Respivant Sciences Gmbh Leczenie stabilizatorami komórek tucznych zaburzeń ogólnoustrojowych
ES2792682T3 (es) 2014-02-10 2020-11-11 Respivant Sciences Gmbh Métodos para el tratamiento de enfermedades pulmonares con estabilizadores de mastocitos
WO2017027402A1 (en) 2015-08-07 2017-02-16 Patara Pharma, LLC Methods for the treatment of systemic disorders treatable with mast cell stabilizers, including mast cell related disorders
US10238625B2 (en) 2015-08-07 2019-03-26 Respivant Sciences Gmbh Methods for the treatment of mast cell related disorders with mast cell stabilizers
WO2018044942A1 (en) 2016-08-31 2018-03-08 Patara Pharma, LLC Cromolyn compositions for treatment of chronic cough due to idiopathic pulmonary fibrosis
EP3522983A4 (de) 2016-10-07 2020-06-03 Respivant Sciences GmbH Cromolynzusammensetzung zur behandlung von lungenfibrose
IT201700030541A1 (it) 2017-03-20 2018-09-20 Federica Livieri Composizione e kit per uso nella prevenzione dell’onicomicosi recidivante

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1423985A (en) 1972-02-15 1976-02-04 Fisons Ltd Pharmaceutical compositions containing bischromonyloxy compounds
US4067992A (en) 1975-09-10 1978-01-10 Fisons Limited Method of treating a psychiatric condition
GB1525294A (en) 1976-06-22 1978-09-20 Fisons Ltd Compositions containing substituted bis-chromonyl compounds
GB1549229A (en) 1976-09-23 1979-08-01 Fisons Ltd High density sodium cromoglycate
GB1569612A (en) 1977-01-13 1980-06-18 Fisons Ltd Disodium cromoglycate pellets or granules
GB1557082A (en) * 1977-01-25 1979-12-05 Fisons Ltd Pharmaceutical mixture containing an antiinflammatory
GB1595220A (en) 1977-12-23 1981-08-12 Fisons Ltd Tablets containing 1,3-bis(2-carboxychromon-5-yloxy)-2-hydroxypropane
GB2086227B (en) 1980-11-05 1984-10-10 Fisons Ltd Sodium cromoglycate reconstitutable powders
SE8303401D0 (sv) * 1983-06-15 1983-06-15 Pharmacia Ab Beredning och dess anvendning
SE8903914D0 (sv) 1989-11-22 1989-11-22 Draco Ab Oral composition for the treatment of inflammatory bowel diseases
DK66493D0 (da) 1993-06-08 1993-06-08 Ferring A S Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB2324962B (en) * 1997-05-10 2001-10-03 Hewlett Healthcare Ltd Treatment of allergic conditions
GB9709451D0 (en) 1997-05-10 1997-07-02 Hewlett Healthcare Limited Treatment of allergic conditions
GB9824604D0 (en) * 1998-11-11 1999-01-06 Hewlett Healthcare Limited Treatment of allergic conditions
DE19900116C2 (de) 1999-01-05 2002-02-14 Univ Muenchen Tech Vorrichtung zum Erzeugen von Brenngas durch allotherme Vergasung von Biomasse

Also Published As

Publication number Publication date
JP2002529413A (ja) 2002-09-10
JP4558207B2 (ja) 2010-10-06
ATE258049T1 (de) 2004-02-15
CA2350519C (en) 2011-09-13
US7258872B1 (en) 2007-08-21
EP1128826A1 (de) 2001-09-05
DE69914360T2 (de) 2004-11-11
DK1128826T3 (da) 2004-04-05
AU1061400A (en) 2000-05-29
US20070036860A1 (en) 2007-02-15
PT1128826E (pt) 2004-06-30
ES2219075T3 (es) 2004-11-16
CA2350519A1 (en) 2000-05-18
GB9824604D0 (en) 1999-01-06
WO2000027392A1 (en) 2000-05-18
EP1128826B1 (de) 2004-01-21

Similar Documents

Publication Publication Date Title
DE69914360D1 (de) Chromone zubereitung zur enteralen wirkstofffreisetzung
Wang et al. The effects and mechanisms of flavonoids on cancer prevention and therapy: focus on gut microbiota
Jiang et al. Mediation of the microbiome-gut axis by oyster (Crassostrea gigas) polysaccharides: A possible protective role in alcoholic liver injury
Madihi et al. Impact of Sumac on postprandialhigh-fat oxidative stress
Wang et al. Separation, antitumor activities, and encapsulation of polypeptide from Chlorella pyrenoidosa
NO20021830D0 (no) Sammensetninger egnet til å forhindre og behandle forkjölelse og influensaliknende symptomer samt fremgangsmåter vedfremstilling derav
Zha et al. Anti-inflammatory effect of soyasaponins through suppressing nitric oxide production in LPS-stimulated RAW 264.7 cells by attenuation of NF-κB-mediated nitric oxide synthase expression
Qiu et al. Structure-anti-inflammatory activity relationship of garlic fructans in mice with dextran sulfate sodium-induced colitis: Impact of chain length
Long et al. Lactobacillus fermentum CQPC08 protects rats from lead-induced oxidative damage by regulating the Keap1/Nrf2/ARE pathway
DE60307749D1 (de) Verwendung von Flavonoid-Derivaten zur Behandlung von atopischem Ekzem
Zhan et al. Dietary 5-demethylnobiletin prevents antibiotic-associated dysbiosis of gut microbiota and damage to the colonic barrier
Lv et al. Determining the effect of malondialdehyde on the IgE‐binding capacity of shrimp tropomyosin upon in vitro digestion
Abedi et al. The inhibition effects of Lentilactobacillus buchneri-derived membrane vesicles on AGS and HT-29 cancer cells by inducing cell apoptosis
Lv et al. Protective effects and potential underlying mechanisms of sodium copper chlorophyllin against ethanol-induced gastric ulcer in mice
Kralovec et al. An aqueous Chlorella extract inhibits IL-5 production by mast cells in vitro and reduces ovalbumin-induced eosinophil infiltration in the airway in mice in vivo
Lv et al. Phytochemical compositions and antioxidant and anti‐inflammatory activities of crude extracts from Ficus pandurata H.(Moraceae)
Al-Khalaf Thyme and thymol effects on induced bronchial asthma in mice
CN105475799A (zh) 一种柑橘类黄酮活性饮料及其制备方法
Wakid et al. Potential anti-toxoplasmosis efficiency of Phoenix dactylifera extracts loaded on selenium nanoparticles
JP2007295919A (ja) 低アレルゲン化ローヤルゼリーの製造方法
CN104922189A (zh) 一种蓝靛果提取物及其在制备肝脏细胞氧化损伤抑制剂中的应用
NO20054670D0 (no) Behandling av intestinale tilstander med N-2,3,3-tetrametylbisyklo[2.2.1]-heptan-2-amid
FR2887549B1 (fr) Nouveaux composes de la famille des iminosucres, leurs utilisations, notamment pour le traitement de maladies lysosomales, ainsi que leur procede de preparation
Han et al. Enhanced cholesterol-lowering and antioxidant activities of soymilk by fermentation with Lactiplantibacillus plantarum KML06
NO20023117D0 (no) Sammensetning for forebygging og/eller behandling av lipidmetabolismeforstyrrelser og allergiske former

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: THORNTON & ROSS LTD., HUDDERSFIELD, YORKSHIRE, GB

8327 Change in the person/name/address of the patent owner

Owner name: TR HEALTHCARE LTD., LINTHWAITE, HUDDERSFIELD, GB